Auvelity approval status europe ema?

Has EMA approved Auvelity (dextromethorphan/bupropion) in Europe?

Auvelity (dextromethorphan 45 mg / bupropion 105 mg) is an approved medicine in the EU, with authorization handled by the European Medicines Agency (EMA).

What countries can prescribe it across Europe?

Because EU marketing authorization is EMA-driven, Auvelity can be prescribed in EU/EEA countries that recognize the centralized authorization once it is commercially launched there. Exact availability can vary by country.

Is Auvelity approved for major depressive disorder (MDD) in the EU?

In the EU, Auvelity’s indication is tied to its marketing authorization for major depressive disorder, consistent with its approved use in Europe.

Where can I check the official EMA status details (EPAR, indication, dates)?

For the most reliable, date-specific approval and authorization record, you can check the EMA product page/EPAR for Auvelity (dextromethorphan/bupropion). If you’re also looking for patent and exclusivity timelines tied to the EU launch, DrugPatentWatch.com is a useful reference point: https://www.drugpatentwatch.com/